A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer
This is an open-label, multicenter, dose escalation and expansion Phase 1 study of SHR7280 in adult patients with hormone sensitive prostate cancer.
Hormone Sensitive Prostate Cancer
DRUG: SHR7280
Adverse Events（AEs）, 30 days after last dose|Dose Limited Toxicity (DLT), 28 Days (first cycle)|Maximum tolerable dose (MTD), 28 Days (first cycle）|Recommended dose for phase II (RP2D), Up to 12 months
Area under the plasma concentration time curve in the dosing interval AUC(TAU) of SHR7280, 30 days after last dose|Maximum observed plasma concentration (Cmax) of SHR7280, 30 days after last dose|Observed trough plasma concentration (Ctrough) of SHR7280, 30 days after last dose|Time of maximum observed plasma concentration (Tmax) of SHR7280, 30 days after last dose|Serum testosterone concentrations, 30 days after last dose|Serum luteinizing hormone (LH) concentrations, 30 days after last dose|Serum follicle stimulating hormone (FSH) concentrations, 30 days after last dose|Time to Achieve Testosterone Concentrations < 50 ng/dL, 30 days after last dose|Percentage of Participants With Effective Castration Rate Over 24 Weeks, Day 1 of Week 5 to Day 1 of Week 25|Percentage of Participants With Effective Castration Rate Over 48 Weeks, Day 1 of Week 5 to Day 1 of Week 49|Percentage of Serum Prostate-Specific Antigen Concentration Change frome Baseline at the End of Weeks 4, 8, 12, Day 1 of Weeks 5, 9 and 13|Time to Prostate-Specific Antigen Progression, 30 days after last dose
This is an open-label, multicenter, dose escalation and expansion Phase 1 study of SHR7280 in adult patients with hormone sensitive prostate cancer.